1Caprice C. Greenberg,Stuart R. Lipsitz,Melissa E. Hughes,Stephen B. Edge,Richard Theriault,John L. Wilson,W. Bradford Carter,Douglas W. Blayney,Joyce Niland,Jane C. Weeks.Institutional Variation in the Surgical Treatment of Breast Cancer: A Study of the NCCN[J]. Annals of Surgery . 2011 (2)
2Cheng Lee,Swartz Michael D,Zhao Hui,Kapadia Asha S,Lai Dejian,Rowan Paul J,Buchholz Thomas A,Giordano Sharon H.Hazard of recurrence among women after primary breast cancer treatment--a 10-year follow-up using data from SEER-Medicare. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology . 2012
3Gamal Rayan,Laura A Dawson,Andrea Bezjak,Anthea Lau,Anthony W Fyles,Qi-Long Yi,Pat Merante,Katherine A Vallis.Prospective comparison of breast pain in patients participating in a randomized trial of breast-conserving surgery and tamoxifen with or without radiotherapy[J]. International Journal of Radiation Oncology, Biology, Physics . 2003 (1)
4Abulkhair Omalkhair,Saghir Nagi,Sedky Lobna,Saadedin Ahmed,Elzahwary Heba,Siddiqui Neelam,Al Saleh Mervat,Geara Fady,Birido Nuha,Al-Eissa Nadia,Sukhun Sana Al,Abdulkareem Huda,Ayoub Menar Mohamed,Deirawan Fawaz,Fayaz Salah,Kandil Alaa,Khat.Modification and implementation of NCCN guidelines on breast cancer in the Middle East and North Africa region. Journal of the National Comprehensive Cancer Network : JNCCN . 2011
7Althuis MD, Dozier JM, Anderson WF, et al. Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol, 2005,34:405-412.
8Jemal A, Siegel R, Ward E, Hao Y, et al. Cancer statistics, 2008. CA Cancer J Clin, 2008 ,58:71-96.
9Pierga JY, Girre V, Laurence V, et al. Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age. Breast, 2004,13:369-375.
10Giordano SH, Hortobagyi GN, Kau SW, et al. Breast cancer treatment guidelines in older women. J Clin Oncol, 2005,23:783- 791.
3Yan D, Qin N,Zhang H, et al. Expression of TNF - alpha leadersequence renders MCF - 7 tumor cells resistant to the cytotoxicityof soluble TNF - alpha[ J]. Breast Cancer Res Treat, 2009, 116(1): 91-102.
4Janji B, Vallar L, Al Tanoury Z, et al. The actin filament cross -linker L - plastin confers resistance to TNF - alpha in MCF - 7breast cancer cells in a phosphorylation - dependent manner[ J].Cell Mol Med, 2010, 14(6A) : 1264 -1275.
5Iniguez MA, Punz6n C, Nieto R, et al. Inhibitory effects of sigma -2receptor agonists on T lymphocyte activation [J].Front Pharmacol,2013,4: 23.
6Strait KA, Stricklett PK, Kohan KM, et al. Identification of twonuclear factor of activated T - cells (NFAT) - response elementsin the 5' - upstream regulatory region of the ET - 1 promoter[ J].Biol Chem, 2010, 285(37) ; 28520 -28528.
7Wang Y, Wang X, Zhao H, et al. Clusterin confers resistance toTNF - alpha - induced apoptosis in breast cancer cells through NF -kappaB activation and Bel - 2 overexpression [ J ]. Chemother,2012,24(6) : 348 -357.
8Nagamoto - Combs K, Combs CK. Microglial phenotype is regula-ted by activity of the transcription factor, NFAT (nuclear factor ofactivated T cells) [ J]. Neurosci, 2010,30(28) : 9641 -9646.
9Madeleine MM, Johnson LG, Malkki M, et al. Genetic variationin proinflammatory cytokines IL6, IL6R,TNF - region, and TN-FRSF1A and risk of breast cancer [ J ]. Breast Cancer Res Treat,2011, 129(3); 887 -899.
10Li X,Zhao Y,Zhang Y, et al. Tumor necrosis factor a stimulatesHer -2 cleavage by activated caspase - B [ J]. Cell Physiol Bio-chem, 2012,30(4) : 889 -897.
